The specter of generic rivalry has consistently loomed around copyright’s famous drug, Viagra, sparking questions about the future of related medicinal stakes. While early years saw substantial profits, the intellectual property lapse has created the path for less expensive alternatives, possibly reducing earnings and posing a significant hazard